Back

Novel biomarker-based risk scores for better stratification of stroke and major bleeding risk in AF patients and OAC therapy optimization.

26 August 2018 (13:20 - 13:40)
Organised by:
Congress Presentation Part of: Biomarker-based approaches for improved atrial fibrillation management Atrial Fibrillation (AF) ESC Premium Access ESC Congress 2018

About the speaker

Photo
Associate Professor Ziad Hijazi

Uppsala University, Uppsala (Sweden)

2 More presentations in this session

Presentation thumbnail
Bleeding risk as one of major hurdles in stroke prevention therapy prescription.
Professor C. Granger (Durham, US)
Presentation thumbnail
How do we assess anticoagulant activity in emergency situations in NOAC treated AF patients?
Professor P. Kamphuisen (Hilversum, NL)

Access the full session

Session thumbnail
Biomarker-based approaches for improved atrial fibrillation management

The Event

Event poster

ESC Congress 2018

26 August 2018 13:20 CET
You may be interested in
thumbnail
Webinar
ACVC Biomarker Talk Series - Biomarkers in atrial fibrillation
24 November 2021
thumbnail
Congress Presentation
Reduction of major adverse and major cardiovascular events in patients with atrial fibrillation and stent implantation treated with left atrial occlusion device vs oral anticoagulants strategy.
26 August 2022
thumbnail
Congress Presentation
Association between thromboembolic and bleeding risk with adverse outcomes in contemporary European atrial fibrillation patients: final analysis from the ESC-EHRA EORP AF general long-term registry
23 April 2021
thumbnail
Congress Session
Atrial fibrillation and cancer: what you should do
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources